Activation of the fibrinolytic, coagulation and plasma kallikrein-kinin systems during and after open heart surgery in children.
Activation of the fibrinolytic, coagulation and plasma kallikrein-kinin systems may be responsible for some of the coagulation disorders and inflammatory sequelae seen after extracorporeal circulation. The activation pattern of these systems was studied in 10 children undergoing open heart surgery with extracorporeal circulation. Blood samples were drawn serially before, during and up to 48 h after surgery. The heparin injection induced a significant elevation of plasmin (PL) (p < 0.05) which stayed elevated during extracorporeal circulation. Antiplasmin (AP) values were reduced at wound closure, while the levels were significantly elevated 48 h postoperatively (p < 0.05). alpha 2-antiplasmin-plasmin (APP) increased significantly perioperatively peaking 10 min after the initiation of cardiopulmonary bypass (p < 0.05). The coagulation markers thrombin-antithrombin (TAT) and the prothrombin fragment F1 & 2 increased significantly, peaking at wound closure and at termination of bypass respectively (p < 0.05). Plasma kallikrein (KK) values increased significantly with subsequent decreased levels of prekallikrein (PKK) and kallikrein inhibitor (KKI) after heparin injection. The KK level stayed elevated during cardiopulmonary bypass (CPB). The proenzyme functional inhibition index (PFI index), defined as the sum of deviations from the control values for proenzyme and functional inhibition values of the coagulation, fibrinolytic and plasma kallikrein-kinin systems, correlated significantly to the duration of cardiopulmonary bypass (p < 0.05). We conclude that open heart surgery in children activates the fibrinolytic, coagulation and plasma kallikrein-kinin systems.
Saatvedt
K
K
Department of Cardiovascular Surgery, Rikshospitalet, The National Hospital, Oslo, Norway.
Lindberg
H
H
Michelsen
S
S
Pedersen
T
T
Geiran
O R
OR
D000933:Antifibrinolytic Agents; D000990:Antithrombin III / Q000032:analysis; D001777:Blood Coagulation; D002315:Cardiopulmonary Bypass; D002675:Child, Preschool; D005260:Female; D005341:Fibrinolysin / Q000032:analysis; D005342:Fibrinolysis; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D007223:Infant; D016234:Kallikrein-Kinin System; D007610:Kallikreins / Q000032:analysis / Q000037:antagonists & inhibitors; D008297:Male; D010447:Peptide Hydrolases / Q000032:analysis; D011288:Prekallikrein / Q000032:analysis; D000979:alpha-2-Antiplasmin / Q000032:analysis
D000933:Antifibrinolytic Agents; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D006493:Heparin; D011288:Prekallikrein; D010447:Peptide Hydrolases; D007610:Kallikreins; D005341:Fibrinolysin